COMBINATION OF EGF/GHRP-6 FOR THE NEUROREGENERATION OF THE CENTRAL NERVOUS SYSTEM FOLLOWING AUTOIMMUNE DAMAGE

摘要

The invention is intended to simulate neuroregeneration of the central nervous system following autoimmune damage. More specifically, the invention relates to the pharmaceutical combination comprising therapeutically-effective concentrations of epidermal growth factor and human growth hormone secretagogue hexapeptide, which is administered to a patient suffering from the symptoms of multiple sclerosis and neuromyelitis optica and which corrects demyelination caused by autoreactive cells in the central nervous system.